Tanvex BioPharma, Inc. (TPE:6541)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
63.30
-0.30 (-0.47%)
Apr 2, 2025, 1:30 PM CST

Tanvex BioPharma Ratios and Metrics

Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
Apr '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Market Capitalization
15,07510,6978,71512,37720,4769,894
Upgrade
Market Cap Growth
22.75%22.75%-29.59%-39.55%106.96%-9.41%
Upgrade
Enterprise Value
16,34711,6039,69113,13319,6929,494
Upgrade
Last Close Price
63.3065.2064.48102.15169.08107.83
Upgrade
PS Ratio
283.38308.48141.91552.433787.6232979.06
Upgrade
PB Ratio
11.6311.9810.618.907.333.78
Upgrade
P/TBV Ratio
12.0712.0710.668.977.353.79
Upgrade
EV/Sales Ratio
334.59334.59157.80586.213642.6131645.92
Upgrade
Debt / Equity Ratio
1.851.852.111.320.630.58
Upgrade
Asset Turnover
0.010.010.020.010.000
Upgrade
Inventory Turnover
0.160.160.010.320.030.00
Upgrade
Quick Ratio
1.171.171.152.689.065.93
Upgrade
Current Ratio
1.941.941.663.449.666.41
Upgrade
Return on Equity (ROE)
-161.17%-161.17%-193.18%-78.41%-56.99%-74.47%
Upgrade
Return on Assets (ROA)
-30.84%-30.84%-42.47%-24.68%-22.00%-33.03%
Upgrade
Return on Capital (ROIC)
-33.29%-33.29%-45.40%-25.78%-22.99%-34.93%
Upgrade
Earnings Yield
-9.16%-12.91%-24.52%-13.26%-7.54%-21.27%
Upgrade
FCF Yield
-8.33%-11.75%-17.29%-11.53%-6.92%-18.74%
Upgrade
Buyback Yield / Dilution
-20.44%-20.44%-9.60%-8.31%-21.32%-9.25%
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.